SEC Form 4 · accession 0001209191-18-002982
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sangeeta N. Bhatia
Director
Period of report
Jan 5, 2018
Accepted (ET)
Jan 9, 2018 · 5:33 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 5, 2018 | M | 10,753 | $126.68 | A | 14,706 | D | |
| Common Stock | Jan 5, 2018 | S | 10,753 | $156.00 | D | 3,953 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $126.68 | Jan 5, 2018 | M | 10,753 | D | — | Jun 3, 2025 | Common Stock | 10,753 | 19,247 | D |
Explanation of responses
- F1Transaction made pursuant to Dr. Bhatia's company-approved trading plan under Rule 10b5-1.
- F2The option vests in 16 quarterly installments from 06/04/2015.